Correction to: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (Gene Therapy, (2016), 23, 12, (857-862), 10.1038/gt.2016.66)

A. Georgiadis; Y. Duran; J. Ribeiro; L. Abelleira-Hervas; S. J. Robbie; B. Sünkel-Laing; S. Fourali; A. Gonzalez-Cordero; E. Cristante; M. Michaelides; J. W.B. Bainbridge; A. J. Smith; R. R. Ali

ArticleOPEN ACCESS

Correction to: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (Gene Therapy, (2016), 23, 12, (857-862), 10.1038/gt.2016.66)

Georgiadis A
Duran Y
Ribeiro J
et al.

Gene Therapy

DOI: 10.1038/s41434-018-0031-x

2Citations

10Readers

Abstract

This Article was originally published under a CC BYNC- SA 4.0 license, but has now been made available under a CC BY 4.0 license. The PDF and HTML versions of the Article have been modified accordingly.

Cite

CITATION STYLE

APA

Georgiadis, A., Duran, Y., Ribeiro, J., Abelleira-Hervas, L., Robbie, S. J., Sünkel-Laing, B., … Ali, R. R. (2018, September 1). Correction to: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (Gene Therapy, (2016), 23, 12, (857-862), 10.1038/gt.2016.66). Gene Therapy. Nature Publishing Group. https://doi.org/10.1038/s41434-018-0031-x

Correction to: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 (Gene Therapy, (2016), 23, 12, (857-862), 10.1038/gt.2016.66)

Abstract

Cite

Register to see more suggestions